Effect of Jaeumgeonbi-Tang on Chronic Subjective Dizziness (NCT05482828) | Clinical Trial Compass
TerminatedPhase 2
Effect of Jaeumgeonbi-Tang on Chronic Subjective Dizziness
Stopped: The Sponser doesn't fund any more
South Korea50 participantsStarted 2010-05
Plain-language summary
The goal of this study is to assess the safety and efficacy of JGT (Jaeumgeonbi-Tang). A randomized, double-blind, parallel-group, placebo-controlled clinical trial was conducted and changes in symptoms and quality of life of the patients were evaluated.
Who can participate
Age range20 Years – 65 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
\[Inclusion Criteria\]
* Chronic subjective dizziness patients, aged from 20 to 65
* DHI (Dizziness Handicap Inventory) score ≥ 24
* Those who can fully comprehend the general protocol of this study and voluntarily agree to participate
\[Exclusion Criteria\]
* Inner ear disease (benign paroxysmal positional vertigo, vestibular neuritis, Meniere's disease, etc.)
* Dizziness secondary to specific diseases such as hypoglycemia, recent stroke (within the last 6 months), or heart disease.
* Use of medications that could influence the result of the study (anticonvulsants, sedatives, antidepressants, sleeping pills, prostate medicine, Parkinson's drug, dementia drug, etc.)
* Pregnancy, breastfeeding, or plans of becoming pregnant
* Functional dyspepsia (persistent, recurring abdominal pain, or discomfort)
* Other allergic diseases
* Ineligibility for other reasons in the opinion of the research clinician (when the physician determines that there are significant physical or mental defects that the patient cannot understand and follow the protocol)
What they're measuring
1
Dizziness handicap Inventory
Timeframe: Change from Baseline DHI score at 4 weeks
Trial details
NCT IDNCT05482828
SponsorKorea Health Industry Development Institute